This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_INSITU_LIVER_GALLBLADDER_BILE_EXALLC for full statistics.
Carcinoma in situ of liver, gallbladder and bile ducts
CD2_INSITU_LIVER_GALLBLADDER_BILE
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditions
|
518527 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
25 |
4. Check minimum number of eventsNone |
25 |
5. Include endpointsNone |
25 |
6. Filter based on genotype QC (FinnGen only) |
25 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
- Parent code in ICD-10
- D01
- Name in latin
- Carcinoma in situ tracheae
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of liver, gallbladder and bile ducts
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ of liver, gallbladder and bile ducts
- Carcinoma in situ of other and unspecified digestive organs
- Carcinoma in situ of other and unspecified digestive organs
- In situ neoplasms
- In situ neoplasms
Similar with less cases:
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 25 | 16 | 9 |
| Unadjusted period prevalence (%) | 0.00 | 0.01 | 0.00 |
| Median age at first event (years) | 60.23 | 56.85 | 66.25 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3033658) Prothrombin time (PT) actual/Normal
15
47
6.48
5.06
11.4
2.6
%
85.8
95.3
0.66
15
47
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
14
42
6.30
4.93
6.4
2.3
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
16
54
6.40
4.67
6.0
2.4
—
—
—
0
0
(3042936) Bacteria identified in Isolate by Culture
10
25
6.00
4.16
2.9
2.4
—
—
—
0
0
(3002256) Pathology report gross observation
9
17
7.61
3.95
1.3
1.3
—
—
—
0
0
(40768797) Stomach Pathology biopsy report
10
29
5.08
3.46
1.4
1.2
—
—
—
0
0
(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
6
7
10.76
3.46
1.8
1.1
—
—
—
0
0
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
17
86
4.03
2.74
8.2
4.4
—
—
—
0
0
(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
16
91
3.09
2.03
11.5
9.6
mmol/l
1.2
1.2
0.46
16
74
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
8
30
3.43
1.93
1.6
1.6
—
—
—
0
0
(3023368) Bacteria identified in Blood by Culture
11
50
3.14
1.91
5.4
3.8
—
—
—
0
0
(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma
15
85
2.91
1.74
10.0
8.1
mmol/l
1.2
1.2
0.09
15
76
(43054903) Holo-transcobalamin II [Moles/volume] in Serum
13
74
2.58
1.42
2.7
2.0
pmol/l
112.7
96.9
—
8
32
(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
13
75
2.53
1.37
2.2
2.8
nmol/l
62.5
75.1
1.09
13
63
(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma
12
67
2.52
1.34
9.1
2.2
u/l
59.4
56.3
0.14
12
60
(3018418) pH of Serum or Plasma
11
59
2.54
1.33
2.5
6.2
—
7.4
—
0
15
(3044889) 12 lead EKG panel
20
148
2.75
1.28
4.9
4.0
—
—
—
0
0
(3014111) Lactate [Moles/volume] in Serum or Plasma
5
20
2.86
1.21
16.6
6.6
mmol/l
2.0
2.0
—
5
20
(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
5
20
2.86
1.21
2.4
4.7
—
—
—
0
0
(40768804) Tissue Pathology biopsy report
13
79
2.34
1.18
3.7
2.0
—
—
—
0
0
(3015377) Calcium [Moles/volume] in Serum or Plasma
11
62
2.38
1.18
2.8
3.7
mmol/l
2.4
2.4
0.08
11
55
(3019150) Specific gravity of Urine by Refractometry
10
55
2.36
1.12
2.1
4.5
—
1.0
—
0
7
(3003694) ABO and Rh group [Type] in Blood
9
51
2.19
1.10
1.4
1.5
—
—
—
0
0
(42870588) Differential panel, method unspecified - Blood
10
57
2.26
1.02
10.1
5.1
—
—
—
0
0
(3011397) Hemoglobin [Presence] in Urine by Test strip
9
54
2.04
0.88
2.7
4.6
—
—
—
0
0
(40761536) Microorganisms panel - Urine sediment
0
24
0.00
0.84
0.0
3.7
—
—
—
0
0
(3017143) Hepatitis C virus Ab [Presence] in Serum
5
23
2.46
0.81
2.0
1.7
—
—
—
0
0
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
5
24
2.34
0.80
1.2
1.7
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
5
24
2.34
0.80
1.2
1.5
—
—
—
0
0
(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
16
124
1.80
0.68
13.6
2.7
u/l
80.9
38.7
0.80
16
114
(3019284) Hepatitis B virus surface Ag [Presence] in Serum
5
29
1.90
0.67
2.2
1.7
—
—
—
0
0
(40758558) Short blood count panel - Blood
8
54
1.70
0.50
2.8
7.2
—
—
—
0
0
(3015736) pH of Urine
11
80
1.67
0.49
2.2
4.3
—
—
—
0
0
(3021601) Nitrite [Presence] in Urine by Test strip
14
111
1.59
0.43
3.1
5.3
—
0.0
—
0
26
(3035350) Ketones [Presence] in Urine by Test strip
14
111
1.59
0.43
2.2
4.4
—
0.0
—
0
24
(21494755) Public health laboratory ask at order entry panel
0
17
0.00
0.42
0.0
1.2
—
—
—
0
0
(3033319) Streptococcus pyogenes Ag [Presence] in Throat
0
18
0.00
0.41
0.0
1.7
—
—
—
0
0
(3009261) Glucose [Presence] in Urine by Test strip
14
114
1.52
0.36
2.4
4.3
—
0.0
—
0
22
(3021960) Folate [Moles/volume] in Serum or Plasma
7
52
1.48
0.35
1.7
1.6
nmol/l
28.7
17.4
—
7
43
(3029937) Albumin [Presence] in Urine by Test strip
5
73
0.61
0.31
3.0
4.6
—
0.0
—
0
24
(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
9
70
1.44
0.31
1.7
3.4
ng/l
1825.8
1482.1
—
9
56
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
14
120
1.38
0.24
2.4
2.5
—
—
—
0
0
(3027273) Bicarbonate [Moles/volume] in Venous blood
0
11
0.00
0.22
0.0
3.6
—
23.6
—
0
11
(4010399)
0
11
0.00
0.22
0.0
1.2
—
—
—
0
0
(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
0
11
0.00
0.22
0.0
4.2
—
48.0
—
0
11
(3004588) Protein electrophoresis panel - Serum or Plasma
0
13
0.00
0.21
0.0
4.5
—
—
—
0
0
(36304419) Bacteria [Presence] in Urine
7
58
1.29
0.21
2.7
2.6
—
—
—
0
0
(3026008) Bacteria identified in Urine by Culture
8
66
1.31
0.20
2.3
3.1
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
9
77
1.26
0.19
5.0
3.3
—
—
—
0
0
(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum
5
43
1.20
0.11
1.2
1.3
—
0.5
—
0
9
(1761868) Lipid panel - Serum or Plasma
5
60
0.79
0.09
1.8
2.7
—
—
—
0
0
(3041096) Erythrocytes [Presence] in Urine by Automated
5
63
0.74
0.09
1.4
3.6
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
10
92
1.14
0.04
2.1
4.5
—
—
—
0
0
(3037467) Urinalysis macro (dipstick) panel - Urine
15
144
1.10
0.01
5.3
4.6
—
—
—
0
0
(3020961) Endomysium IgA Ab [Titer] in Serum
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
(3017895) Helicobacter pylori Ab [Units/volume] in Serum
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
(1001926) Buprenorphine [Presence] in Urine by Screen method
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3017766) Complement C4 [Mass/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.2
—
0.2
—
0
5
(40768800) Prostate Pathology biopsy report
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
(3028300) Cannabinoids [Presence] in Urine
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(3050129) First trimester maternal screen panel - Serum or Plasma
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3037756) Immunofixation for Serum or Plasma
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3027008) Opiates [Presence] in Urine
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(40760888) Immunoglobulin light chains.free panel - Serum
0
6
0.00
0.00
0.0
6.8
—
—
—
0
0
(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3021387) Prolactin [Units/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
1.8
—
544.0
—
0
6
(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3003327) Ova and parasites identified in Stool by Light microscopy
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum
0
8
0.00
0.00
0.0
5.3
—
—
—
0
0
(3023150) Myeloperoxidase Ab [Units/volume] in Serum
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3000764) Benzodiazepines [Presence] in Urine
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3016879) Cocaine [Presence] in Urine
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(40768793) Breast Pathology biopsy report
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3052851) Hemolysis interference index of Serum or Plasma
0
7
0.00
0.00
0.0
5.3
—
—
—
0
0
(3027944) Amphetamines [Presence] in Urine
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3024891) Influenza virus A+B Ag [Presence] in Specimen
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay
0
5
0.00
0.00
0.0
7.2
—
289.9
—
0
5
(3042111) Morphology [Interpretation] in Bone marrow Narrative
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3011288) Drugs identified in Urine by Screen method
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3000620) Complement C3 [Mass/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.2
—
1.2
—
0
5
(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(36305247) Microscopic observation [Identifier] in Isolate by Gram stain
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(3008898) HLA-B27 [Presence]
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_LIVER_GALLBLADDER_BILE – Carcinoma in situ of liver, gallbladder and bile ducts
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).